





Figure 1 (A)-(C) (continued)

D



E




Figure 1 (D)-(E) (end)

3/27





Figure 2(A)-(C) (continued)

4/27

D



E





Figure 2(D)-(E) (continued)

5/27

F



G




Figure 2(F)-(G) (end)

6/27




Figure 3

7/27






Figure 4

8/27

A



B



C




Figure 5(A)-(C) (continued)

D

Viral Titer in Hindlimbs

EV-A71 Log₁₀ Viral Titre (PFU/mL)

■ AAVDJ-GFPgRNA
■ AAVDJ-EV71gRNA 1 x 10e11 vgs
■ AAVDJ-EV71gRNA 1 x 10e12 vgs

E

Viral Titer in Brain

EV-A71 Log₁₀ Viral Titre (PFU/mL)

■ AAVDJ-GFPgRNA
■ AAVDJ-EV71gRNA 1 x 10e11 vgs
■ AAVDJ-EV71gRNA 1 x 10e12 vgs

Figure 5(D)-(E) (continued)

10/27





Figure 5(F)-(G) (end)

11/27

A



B




Figure 6(A)-(B) (continued)

12/27




Figure 6(C) (end)




Figure 7(A)-(B) (continued)




Figure 7(C)-(D) (continued)




Figure 7(E)-(F) (continued)




Figure 7(G)-(H) (end)




Figure 8(A)-(B) (continued)




Figure 8(C)-(D) (continued)




Figure 8(E)-(F) (continued)

20/27




Figure 8(G)-(H) (end)

21/27




Figure 9




Figure 10 (continued)




Figure 10 (end)




Figure 11(A) (continued)




Figure 11 (B) (continued)





Figure 11 (C) (continued)

27/27

D EV71 inhibition assay at MOI 1000K**Figure 11(D) (end)**